224 related articles for article (PubMed ID: 30526126)
21. VLPs and particle strategies for cancer vaccines.
Ungaro F; Conte C; Quaglia F; Tornesello ML; Buonaguro FM; Buonaguro L
Expert Rev Vaccines; 2013 Oct; 12(10):1173-93. PubMed ID: 24124878
[TBL] [Abstract][Full Text] [Related]
22. Generation and preclinical immunogenicity study of dengue type 2 virus-like particles derived from stably transfected mosquito cells.
Suphatrakul A; Yasanga T; Keelapang P; Sriburi R; Roytrakul T; Pulmanausahakul R; Utaipat U; Kawilapan Y; Puttikhunt C; Kasinrerk W; Yoksan S; Auewarakul P; Malasit P; Charoensri N; Sittisombut N
Vaccine; 2015 Oct; 33(42):5613-5622. PubMed ID: 26382602
[TBL] [Abstract][Full Text] [Related]
23. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
[TBL] [Abstract][Full Text] [Related]
24. B19-VLPs as an effective delivery system for tumour antigens to induce humoral and cellular immune responses against triple negative breast cancer.
Jiménez-Chávez ÁJ; Nava-García BK; Bustos-Jaimes I; Moreno-Fierros L
Immunol Lett; 2021 Nov; 239():77-87. PubMed ID: 34508790
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of H1N1 influenza virus-like particles produced in Nicotiana benthamiana.
Shoji Y; Prokhnevsky A; Leffet B; Vetter N; Tottey S; Satinover S; Musiychuk K; Shamloul M; Norikane J; Jones RM; Chichester JA; Green BJ; Streatfield SJ; Yusibov V
Hum Vaccin Immunother; 2015; 11(1):118-23. PubMed ID: 25483524
[TBL] [Abstract][Full Text] [Related]
26. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
Janitzek CM; Matondo S; Thrane S; Nielsen MA; Kavishe R; Mwakalinga SB; Theander TG; Salanti A; Sander AF
Malar J; 2016 Nov; 15(1):545. PubMed ID: 27825348
[TBL] [Abstract][Full Text] [Related]
27. Formulation and stabilization of recombinant protein based virus-like particle vaccines.
Jain NK; Sahni N; Kumru OS; Joshi SB; Volkin DB; Russell Middaugh C
Adv Drug Deliv Rev; 2015 Oct; 93():42-55. PubMed ID: 25451136
[TBL] [Abstract][Full Text] [Related]
28. Particle-based platforms for malaria vaccines.
Wu Y; Narum DL; Fleury S; Jennings G; Yadava A
Vaccine; 2015 Dec; 33(52):7518-24. PubMed ID: 26458803
[TBL] [Abstract][Full Text] [Related]
29. Comparative efficacy of virus like particle (VLP) vaccine of foot-and-mouth-disease virus (FMDV) type O adjuvanted with poly I:C or CpG in guinea pigs.
Terhuja M; Saravanan P; Tamilselvan RP
Biologicals; 2015 Nov; 43(6):437-43. PubMed ID: 26493006
[TBL] [Abstract][Full Text] [Related]
30. Meeting report VLPNPV: Session 8: Vaccines I.
Thiriot DS
Hum Vaccin Immunother; 2014; 10(10):3078-9. PubMed ID: 25483643
[TBL] [Abstract][Full Text] [Related]
31. Plant-derived virus-like particles as vaccines.
Chen Q; Lai H
Hum Vaccin Immunother; 2013 Jan; 9(1):26-49. PubMed ID: 22995837
[TBL] [Abstract][Full Text] [Related]
32. Immunological basis for enhanced immunity of nanoparticle vaccines.
Kelly HG; Kent SJ; Wheatley AK
Expert Rev Vaccines; 2019 Mar; 18(3):269-280. PubMed ID: 30707635
[TBL] [Abstract][Full Text] [Related]
33. Antigen delivery by virus-like particles for immunotherapeutic vaccination.
Al-Barwani F; Donaldson B; Pelham SJ; Young SL; Ward VK
Ther Deliv; 2014 Nov; 5(11):1223-40. PubMed ID: 25491672
[TBL] [Abstract][Full Text] [Related]
34. Virus-like antigen display for cancer vaccine development, what is the potential?
Sander AF; Lollini PL
Expert Rev Vaccines; 2018 Apr; 17(4):285-288. PubMed ID: 29560746
[No Abstract] [Full Text] [Related]
35. A bivalent virus-like particle based vaccine induces a balanced antibody response against both enterovirus 71 and norovirus in mice.
Wang X; Ku Z; Dai W; Chen T; Ye X; Zhang C; Zhang Y; Liu Q; Jin X; Huang Z
Vaccine; 2015 Oct; 33(43):5779-5785. PubMed ID: 26424606
[TBL] [Abstract][Full Text] [Related]
36. A virus-like particle vaccine candidate for influenza A virus based on multiple conserved antigens presented on hepatitis B tandem core particles.
Ramirez A; Morris S; Maucourant S; D'Ascanio I; Crescente V; Lu IN; Farinelle S; Muller CP; Whelan M; Rosenberg W
Vaccine; 2018 Feb; 36(6):873-880. PubMed ID: 29306508
[TBL] [Abstract][Full Text] [Related]
37. Prevailing Sydney like Norovirus GII.4 VLPs induce systemic and mucosal immune responses in mice.
Huo Y; Wan X; Ling T; Wu J; Wang Z; Meng S; Shen S
Mol Immunol; 2015 Dec; 68(2 Pt A):367-72. PubMed ID: 26375574
[TBL] [Abstract][Full Text] [Related]
38. BALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8.1, gB, and gH/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV.
Barasa AK; Ye P; Phelps M; Arivudainambi GT; Tison T; Ogembo JG
Oncotarget; 2017 May; 8(21):34481-34497. PubMed ID: 28404899
[TBL] [Abstract][Full Text] [Related]
39. Cowpea Mosaic Virus Nanoparticles and Empty Virus-Like Particles Show Distinct but Overlapping Immunostimulatory Properties.
Wang C; Beiss V; Steinmetz NF
J Virol; 2019 Nov; 93(21):. PubMed ID: 31375592
[TBL] [Abstract][Full Text] [Related]
40. Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice.
Hinkula J; Devignot S; Åkerström S; Karlberg H; Wattrang E; Bereczky S; Mousavi-Jazi M; Risinger C; Lindegren G; Vernersson C; Paweska J; van Vuren PJ; Blixt O; Brun A; Weber F; Mirazimi A
J Virol; 2017 May; 91(10):. PubMed ID: 28250124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
